Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer
Status:
Completed
Trial end date:
2019-07-11
Target enrollment:
Participant gender:
Summary
Pancreatic cancer is a common malignancy of digestive system with gradually increasing
incidence, is the fourth and seventh leading cause of cancer-related mortality in the world
(1) and China (2) according to the statistics in 2014. The vast majority of patients were
confirmed as locally advanced or distantly metastatic disease at diagnosis with an estimated
five-year survival rate of 4% (3) due to occlusive development and rapid progress. Advanced
pancreatic cancer is characterized by poor prognosis.